巨核细胞转录因子ARID3A抑制白血病发病机制
该研究探讨急性巨核细胞白血病(AMKL)的分子发病机制,发现miR-125b通过转录后抑制ARID3A与GATA1s协同驱动白血病发生。ARID3A在正常造血中促进巨核细胞分化并介导TGFβ诱导的凋亡和细胞周期阻滞,其缺失导致双分化阻滞,恢复ARID3A可缓解分化阻滞,为治疗提供新策略。
要点
- miR-125b转录后抑制ARID3A是AMKL发病的关键事件
- ARID3A与GATA1协同促进巨核细胞分化并介导TGFβ凋亡
- 恢复ARID3A可解除AMKL分化阻滞,具治疗潜力
核心结论
- miR-125b通过抑制ARID3A与GATA1s协同驱动AMKL,恢复ARID3A可解除分化阻滞。
研究设计与样本
- 利用正向和反向遗传学方法研究AMKL发病机制及ARID3A功能。
主要发现
- 染色体21编码的miR-125b与Gata1s协同驱动白血病发生。
- ARID3A是miR-125b协同作用的主要靶点。
- ARID3A与GATA1协同促进巨核细胞分化,并与SMAD2/3复合物介导TGFβ诱导的凋亡和细胞周期阻滞。
- 敲低ARID3A导致巨核/红系双分化阻滞,恢复ARID3A可缓解AMKL患者来源异种移植物的分化阻滞。
临床怎么用
- 恢复ARID3A表达可能成为治疗AMKL的有前景策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the plasticity of hematopoietic stem and progenitor cells, multiple routes of differentiation must be blocked in the the pathogenesis of acute myeloid leukemia, the molecular basis of which is incompletely understood. We report that posttranscriptional repression of the transcription factor ARID3A by miR-125b is a key event in the pathogenesis of acute megakaryoblastic leukemia (AMKL). AMKL is frequently associated with trisomy 21 and GATA1 mutations (GATA1s), and children with Down syndrome are at a high risk of developing the disease. The results of our study showed that chromosome 21-encoded miR-125b synergizes with Gata1s to drive leukemogenesis in this context. Leveraging forward and reverse genetics, we uncovered Arid3a as the main miR-125b target behind this synergy. We demonstrated that, during normal hematopoiesis, this transcription factor promotes megakaryocytic differentiation in concert with GATA1 and mediates TGFβ-induced apoptosis and cell cycle arrest in complex with SMAD2/3. Although Gata1s mutations perturb erythroid differentiation and induce hyperproliferation of megakaryocytic progenitors, intact ARID3A expression assures their megakaryocytic differentiation and growth restriction. Upon knockdown, these tumor suppressive functions are revoked, causing a blockade of dual megakaryocytic/erythroid differentiation and subsequently of AMKL. Inversely, restoring ARID3A expression relieves the arrest of megakaryocytic differentiation in AMKL patient-derived xenografts. This work illustrates how mutations in lineage-determining transcription factors and perturbation of posttranscriptional gene regulation can interact to block multiple routes of hematopoietic differentiation and cause leukemia. In AMKL, surmounting this differentiation blockade through restoration of the tumor suppressor ARID3A represents a promising strategy for treating this lethal pediatric disease.
引用
- Alejo-Valle O, Weigert K, Bhayadia R, et al. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. Blood. 2022. PMID: 34570885. doi:10.1182/blood.2021012231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。